Should S-1 be better than capecitabine for patients with advanced gastric cancer in Asia? A systematic review and meta-analysis.

ABSTRACT:

Background

S-1 or capecitabine (Cap) containing treatment is an increasingly used strategy in patients with advanced gastric cancer in Asia. It is unclear whether there is sufficient evidence to support which regimen is better.

Methods

A systematic review of retrospective studies and randomized controlled trials (RCTs) comparing S-1 with Cap containing treatment in advanced gastric cancer patients was performed. Embase, PubMed, ClinicalTrials.gov, Cochrane Library, and reference lists were searched from inception until August 2018 for relevant studies. Outcomes of interest included 1-year overall survival (OS), 1-year progression-free survival (PFS), objective response rate (ORR), and adverse events. Meta-analyses of the random events were performed. We also performed sensit

SUBMITTER: Ye Z 

PROVIDER: S-EPMC6312060 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature